MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "etc): Treatment"

  • 2016 International Congress

    Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort

    V. Sung, D. Stamler, D.O. Claassen (Birmingham, AL, USA)

    Objective: To evaluate the sustained safety and efficacy following overnight switch from tetrabenazine (TBZ) to deutetrabenazine in patients with chorea associated with Huntington disease (HD).…
  • 2016 International Congress

    Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

    C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

    Objective: To assess if deutetrabenazine treatment of chorea associated with HD resulted in changes in QoL, Patient Global Impression of Change (PGIC), or Clinical Global…
  • 2016 International Congress

    Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study

    S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On behalf of First-HD HSG Investigators (Boston, MA, USA)

    Objective: The Swallowing Disturbance Questionnaire (SDQ) was administered to patients with Huntington disease (HD) as part of a randomized, controlled study of deutetrabenazine for the…
  • 2016 International Congress

    Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease

    S. Zittel, V. Tadic, C. Moll, A. Fellbrich, N. Brüggemann, D. Rasche, T. Bäumer, V. Tronnier, A. Münchau (Luebeck, Germany)

    Objective: To prospectively evaluate the effect of bilateral pallidal deep brain stimulation (DBS) on motor symptoms, activities of daily living and quality of life in…
  • 2016 International Congress

    Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study

    R. Miguel, M. Mendonça, R. Barbosa, F. Ladeira, T. Lampreia, J. Vale, P. Bugalho (Lisbon, Portugal)

    Objective: To assess the efficacy and side-effects of TBZ in Huntington disease (HD), vascular chorea, tics, dystonia, oromandibular dyskinesia and other tardive syndromes (TS). Background:…
  • 2016 International Congress

    Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington´s disease – A case report

    T.T.C. Capato, R.G. Cury, R. Gimaães, E.T. Fonoff, M.S. Haddad (São Paulo, Brazil)

    Objective: The aim of this study was to analyse the motor outcome before and after 6 month follow-up in a HD patient treated by GPi-DBS.…
  • 2016 International Congress

    Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea

    A. Robichaux-Viehoever, A. Ananth, Y.M. Kim, A. Hanson-Kahn, R. Cox, G. Enns, J. Strober, M. Willing, B. Schlaggar, J. Bernstein, Y. Wu (San Francisco, CA, USA)

    Objective: We describe the clinical course of 6 patients with de novo GNAO1 mutations with severe chorea, developmental delay and hypotonia, but the absence of…
  • 2016 International Congress

    A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)

    H.H. Fernandez, S.A. Factor, R.A. Hauser, J. Jimenez-Shahed, W. Ondo, M.S. LeDoux, D. Shprecher, T. Simuni, D. Stamler, K.E. Anderson (Cleveland, OH, USA)

    Objective: To determine the efficacy and safety of deutetrabenazine (DTB) as a treatment for tardive dyskinesia (TD). Background: There is no approved treatment for TD,…
  • 2016 International Congress

    A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome

    J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T.K. Murphy, D. Shprecher, D. Stamler (Houston, TX, USA)

    Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…
  • « Previous Page
  • 1
  • 2
  • 3

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley